Iminostilbene, a chemical precursor of carbamazepine, is an orally active inhibitor of PKM2 (Pyruvate Kinase M2) and COX2 (Cyclooxygenase-2). It inhibits PKM2's interaction with HIF-1α and STAT3, reducing COX2 and iNOS expression. This suppresses macrophage-mediated inflammatory responses and improves myocardial ischemia/reperfusion (MI/R) injury, offering promise for research in inflammation regulation, cardiovascular, and macrophage-mediated immune-related diseases.
- Precursor of carbamazepine
- Orally active inhibitor of PKM2 and COX2
- Inhibits PKM2 and its interaction with HIF-1α and STAT3
- Reduces COX2 and iNOS expression
- Suppresses LPS-induced inflammatory cytokine release
- Suppresses macrophage-mediated inflammatory responses
- Improves myocardial ischemia/reperfusion (MI/R) injury
- Supports research in inflammation, cardiovascular, and immune-related diseases